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We have tested a new type of immunoliposomes which may effectively mediate the targeting of enzymes to be used for site-specific prodrug activation 
(immuno-enzymosomes). The enzyme j%glucuronidase, capable of activating the prodrug epirubicin-glucuronide ( pi-glu), was coupled to the 
external surface of immunoliposomes directed towards ovarian cancer cells. A significant increase in cytotoxicity of the prodrug epi-glu was shown 
when the in vitro cultured cancer cells were pretreated with these immuno-enzymosomes. 
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1. INTRODUCTION 
The use of current antitumor drugs is strongly limited 
by the lack of selectivity for cancer cells. During the last 
decade immunoliposomes (antibody-directed liposo- 
mes) have been studied to establish their potential in 
cancer therapy as a tool to achieve efficient site- specific 
drug delivery [l-7]. Despite progress made in targeting 
drug-containing immunoliposomes to cancer cells in 
vitro and in vivo, considerable problems still remain 
with respect to antitumor efficacy. In order to deliver 
the encapsulated rug effectively to the target cell the 
drug must remain within the vesicle during the transport 
to the target site. It has to exert its action after binding 
of the immunoliposomes to the receptors on the target 
cell surface. However, even though immunoliposomes 
may be tightly bound to the target cell surface, this is 
not a guarantee for intracellular delivery of the li- 
posome contents. In principle, two pathways for drug 
entry into the target cell can be envisaged. Firstly, up- 
take of the immunoliposomes by the cells or fusion with 
the cells, followed by intracellular release of the drug 
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may occur [8,9]. Unfortunately, however, many tumor 
cells are not capable of internalizing liposomes effi- 
ciently. Secondly, release of the encapsulated rug in the 
close proximity of the target cells may result in a consid- 
erable cellular drug uptake. In this case it is necessary 
that the released drug is rapidly taken up by the tumor 
cells, which depends on its physicochemical 
nature (e.g. lipophilicity). Methods to construct immu- 
noliposomes to release entrapped agents through envi- 
ronmental manipulations (e.g. in response to changes in 
pH or temperature) are being investigated [l&12]. 
Another approach to generate sufficient and site-spe- 
cific antitumor activity concerns enzymes, capable of 
locally converting relatively non-toxic prodrugs into ac- 
tive cytotoxic agents. These enzymes can be coupled to 
the external surface of immunoliposomes directed to- 
wards cancer cells. After binding of these immuno-enzy- 
mosomes to the target cells, a prodrug is administered 
and the active drug is generated in the close proximity 
of the tumor cell (Fig. 1). The use of enzymes for selec- 
tive prodrug activation at the tumor site has been de- 
scribed earlier as antibody-directed enzyme prodrug 
therapy (ADEPT). In this approach, enzyme is linked 
to an antibody that binds to an antigen preferentially 
expressed on tumor cells. The few studies carried out 
with antibody-enzyme conjugates in in vitro and in vivo 
models showed that selective conversion of prodrug in- 
to active drug at the tumor site can be obtained [ 13- 161. 
In this report, we describe the coupling of the enzyme 
/3_glucuronidase (GUS) to the external surface of immu- 
noliposomes, specifically directed against human ovar- 
ian carcinoma cells. These immuno-enzymosomes were 
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tested for their enzymatic activity, stability and capabil- 
ity to bind to the tumor cells. Recently, it has been 
reported that the relatively non-toxic glucuronide pro- 
drug epirubicin-glucuronide (epi-glu) can be converted 
to the parent drug epirubicin by GUS [15]. We demon- 
strate that epi-glu can preferentially kill human ovarian 
cancer cells that were previously exposed to the im- 
muno-enzymosomes. 
2. MATERIALS AND METHODS 
2.1. Materials 
DMEM and fetal calf serum were obtained by Flow Laboratories 
(Irving, Scotland, UK). F(ab’), fragments of OV-TL3 were donated 
by Centocor Europe BV (Leiden, The Netherlands). GUS from E. coli 
K12 was purchased from Boehringer (Mannheim, Germany). Imi- 
nothiolane was purchased from Pierce (Oud-Beijerland, The Nether- 
lands). EggPC and eggPG were a gift from Lipoid KG (Ludwigshafen, 
Germany) and Nattermann GmbH (Cologne, Germany), respectively. 
Cholesterol, SRB, DTT, TCA and N-ethyhnaleimide were obtained 
from Sigma Chemical Co. (St. Louis, USA). 
2.2. Cancer cell line and cell culture 
The human ovarian cancer cell lines NIH:OVCAR-3 [ 171 and A2780 
[ 181 were maintained in Dulbecco’s Modified Eagle’s Medium supple- 
mented with 10% fetal calf serum, L-glutamine (2 mM), penicillin (100 
units/ml) and streptomycin (100 &ml). 
2.3. Preparation of Fab’-fragments 
The monoclonal antibody OV-TL3 is directed against human ovar- 
ian carcinoma [19]. F(ab’), fragments of OV-TL3 were incubated with 
20 mM DTT in acetate buffer at pH 5.5 (100 mM sodium acetate, 63 
mM sodium chloride, 1 mM EDTA) for at least 90 min at room 
temperature [2]. DTT was removed by applying the incubation mix- 
ture onto a Sephadex G-25M column (PD-10; Pharmacia, Woerden, 
The Netherlands). Elution occurred with acetate buffer, pH 6.5 (100 
mM sodium acetate, 40 mM sodium chloride, 1 mM EDTA, deoxy- 
genated and flushed with nitrogen before use). Fab’ fragments appear- 
ing in the void volume were used immediately for covalent attachment 
to freshly prepared MPB-PE liposomes (see section 2.4). 
2.4. Preparation of immunoliposomes 
N-[4-(p-Maleimidophenyl)butyryl]phosphatidylethan olamine 
(MPB-PE) was synthesized, purified and analyzed as described before 
[2,20]. MPB-PE was incorporated into the liposomal bilayers to 
allow covalent coupling of Fab’ fragments to the liposomal surface. 
The composition of the bilayer of the liposomes used was 
eggPC:eggPG:CHOL:MPB-PE at a molar ratio of 38.5:4:16:1.5. A 
mixture of the appropriate amounts of lipids in chloroform was evap- 
orated to dryness by rotary-evaporation at 35’C under reduced pres- 
sure. After flushing with nitrogen for at least 20 min, the lipid tilm was 
hydrated in HEPES buffer (20 mM HEPES, 149 mM NaCI, 1 mM 
EDTA, pH 7.4). The resulting liposome dispersion was sequentially 
extruded through polycarbonate membrane filters with 0.6pm and 0.2 
pm pore size (Unipore, Biorad, Richmond, CA) under nitrogen pres- 
sures up to 0.8 MPa. After extrusion the HEPES buffer outside the 
liposomes was replaced by acetate butfer, pH 6.5, using ultraccntrifu- 
gation (100,000 x g; 45 min). The freshly prepared liposomes were 
mixed with freshly prepared Fab’ fragments (concentrations during 
incubation ranged from 612 pmol total lipid (TL)/ml and 0.25-0.35 
mg Fab’/ml, respectively). The coupling reaction was carried out over- 
night at 4°C under constant rotation in nitrogen atmosphere. Finally, 
the immunoliposomes were separated from unconjugated Fab’ frag- 
ments by ultracentrifugal sedimentation at 100,000 x g during 30 min. 
The pellet was resuspended and washed twice with HEPES buffer. 
MPB-PE-containing liposomes not incubated with Fab’ fragments are 
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referred to as MPB-PE liposomes. Liposome dispersions were stored 
at 4°C. 
2.5. Enzyme thiolation 
GUS was first purified by gel filtration on a Sephadex G-25M 
column (PD-10) with phosphate buffered saline (PBS). To introduce 
extra thiol groups, GUS was incubated with iminothiolane at a ratio 
of f 50 pg iminothiolane per mg GUS in PBS (pH 7.2) containing 1 
mM EDTA for 45 min at room temperature [15]. This results in the 
addition of, on the average, approximately 4 thiol groups per GUS 
molecule without a significant effect on the enzyme activity. Imino- 
thiolane and PBS were removed by applying the incubation mixture 
onto a Sephadex G-25M column. Pre-equilibration and elution oc- 
curred with acetate buffer, pH 6.5. Modified GUS appearing in the 
void volume was used immediately for covalent attachment to freshly 
prepared MPB-PE liposomes. 
The enzyme activity was measured with p-nitrophenyl-@-glucu- 
ronide (10 mM in PBS/O.l% BSA). Samples (10 ~1) were incubated 
with this substrate (190 ~1) for 30 min at 37’C. The reaction was 
stopped by the addition of 50~1 of 1 M glycine @H 10.6) and absorb- 
ance was read at 405 nm. 
2.6. Coupling of thiolated GUS to liposomes 
The coupling procedure of GUS to MPB-PE liposomes is similar 
to the coupling procedure of Fab’ to liposomes. The freshly prepared 
MPB-PE liposomes were mixed with freshly thiolated GUS (concen- 
trations during incubation ranged from 612 ,umol Turn1 and 0.25- 
0.35 mg GUS/ml, respectively, resulting in an incubation ratio of 
about 30 pug GUS/pmol TL). The coupling reaction and separation of 
unconjugated thiolated GUS was carried out as described under sec- 
tion 2.4. GUS-liposomes are further referred to as enzymosomes. 
Liposomes to which both enzyme and Fab’ are coupled are referred 
to as immuno-enzymosomes. For the preparation of the immuno- 
enzymosomes, MPB-PE liposomes were incubated with Fab’ frag- 
ments and GUS present in the same incubation mixture under the 
conditions mentioned in section 2.4. 
2.7. Liposome characterization 
Lipid phosphate was determined by the calorimetric method of 
Fiske and Subbarow [21]. The enzyme activity was measured with 
p-nitrophenyl-/3-n-glucuronide as described above in section 2.5. The 
amount of protein coupled to the liposomes was determined by the 
method of Wessel and Flilgge [22], with bovine serum albumin as 
standard. The total amount of monoclonal antibody and/or enzyme 
coupled to the liposomes was expressed as pug of protein per pm01 of 
TL. The amount of enzyme protein coupled to immunoenzymosomes 
was estimated by comparison with enzymosomes, to which only en- 
zyme is coupled. 
Mean particle size was determined by dynamic light scattering with 
a Malvem 4700 system using a 25 mW helium-neon laser and the 
AUTOMEASURE vsn. 3.2 software (Malvem Ltd., Malvem, UK). 
For viscosity and refractive index the values of pure water were used. 
As a measure of the particle size distribution of the dispersion the 
system reports a polydispersity index. This index ranges from 0.0 for 
an entirely monodisperse up to 1.0 for a completely polydisperse 
dispersion. 
2.8. In vitro cell binding 
Specific cell binding of immuno-enzymosomes in vitro was studied 
with OVCAR3 cells. The cell line A2780 served as a control cell 
group. Cells were harvested with PBYEDTA (0.02%), washed and 
diluted with PBS to a suspension containing 1 x 10’ cells/ml. Immuno- 
enzymosomes, enzymosomes and immunoliposomes were diluted to 
a lipid concentration of about 1 pmol/ml. The various liposome types 
were incubated with an equal volume of the cell suspension in PBS 
during 1 h at room temperature. Unbound liposomes were separated 
from the cells by centrifugation (300 x g, 3 min). The cell pellet was 
washed twice with 4 ml of PBS containing 1% BSA. The degree of cell 
binding was assessed by measuring the enzyme activity in the redis- 
persed cell pellet. 
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2.9. In vitro cytotoxicity 
The prodrug epi-glu was isolated from mine from patients treated 
with epirubicin as described before [15]. The in vitro cytotoxicity of 
epi-glu was determined with and without pretreatment of the tumor 
cells with the various types of liposomes. A suspension of OVCAR-3 
cells in PBS was incubated with immuno-enzymosomes, enzymo- 
somes, immunoliposomes or PBS for 60 min at 4°C (10’ cells/ml; 5-10 
pm01 TLJml). Unbound liposomes were removed by centrifugation (5 
min, 300 x g). The cell pellet was washed twice with PBS and resus- 
pended in MEM (2 x lo6 cells/ml). Then, 2 x lo4 cells were seeded in 
a U-bottom 96-well plate. The prodrug was added to provide a final 
concentration of 10 PM. After incubation for 24 h fresh medium 
(DMEM) was added and the cells were grown for another 72 h. The 
cytotoxic effects of epi-glu were determined using the SRB-assay [23]. 
The cultures were fixed with 5% ice-cold trichloric acetic acid (TCA) 
at 4°C for l-2 h, washed with water and stained with 0.4% sulfo- 
rhodamine-B solution (SRB). Fifteen minutes later, the plates were 
washed with 1% acetic acid and air-dried. The bound dye was dis- 
solved with 10 mM Tris and the optical density was measured at 540 
nm using a Titertek multiscan (Flow laboratories, Helsinki, Finland). 
3. RESULTS AND DISCUSSION 
Fig. 1 illustrates the strategy of converting a prodrug 
to the active drug by cell-bound immuno-enzymosomes. 
The impetus for examining this concept comes from our 
observations that efficient binding of cytostatic-con- 
taining immunoliposomes to ovarian carcinoma cells in 
vivo is not inducing a corresponding increase in antitu- 
mor response [2,3]. We have addressed three basic ques- 
tions. (1) Is it possible to couple GUS to the outer 
surface of immunoliposomes with preservation of its 
enzymatic activity? (2) Does the presence of GUS (MW 
280 kDa) on the outer surface of the immunoliposomes 
prevent the Fab’ (MW 50 kDa) -target cell interaction? 
(3) Are tumor cell-associated immuno-enzymosomes 
able to activate the glucuronide prodrug epi-glu? 
Immuno-enzymosomes were prepared by coupling 
GUS and Fab’-fragments of the monoclonal antibody 
OV-TL3 in one incubation step to liposomes containing 
the anchor molecule MPB-PE. The maleimide group of 
this anchor molecule reacts with a thiol group, forming 
a stable thio-ether bond [20]. Incubation of non-modi- 
fied GUS with MPB-PE liposomes resulted in a low 
coupling efficiency (results not shown). Therefore, be- 
fore coupling of GUS to the liposomes, extra SH- 
groups were introduced in the molecule by incubation 
with iminothiolane. Results on the coupling of Fab’ and 
GUS to MPB-PE liposomes are presented in Table I. 
Fab’ (immunoliposomes: 13.0 f 2.5 ,@pmol TL; n = 5) 
was coupled to a higher extent to the MPB-PE li- 
posomes than GUS (enzymosomes: 4.7 + 1.4 pg/pmol 
TL; n = 5). The respective coupling ratios were not sig- 
nificantly different when both proteins were coupled to 
the liposomes simultaneously (immuno-enzymosomes: 
Fab’ 13.5 f: 4.1 @pm01 TL and GUS 4.0 f 1.6 pg/ 
pmol TL; 12 = 4). It was estimated that around 400 Fab 
and 20 GUS molecules were present on one immuno- 
enzymosome particle. The coupling procedure had only 
a minor effect on the enzyme activity (results not 
shown). On the day of preparation, the mean diameter 
was found to be about 0.29 pm and 0.30 ,um with ac- 
ceptable polydispersity indices for enzymosomes and 
immuno-enzymosomes, respectively. The mean particle 
size and enzyme activity did not change significantly 
during storage at 4°C for a period of 4 weeks (results 
not shown). A sharp increase in particle size and 
polydispersity index, however, was observed when the 
GUS coupling ratio of the (immuno)enzymosomes x- 
ceeded 10 ,@pmol TL. This implies that not more than 
about 50 GUS molecules can be covalently linked to the 
liposomes without occurrence of aggregation. There- 
fore, the cell binding and cytotoxicity experiments were 
performed with liposomes with a GUS coupling ratio 
lower than 10 ,ug GUS/pm01 TL. 
The potential problem of GUS-induced hindrance of 
Fab’-mediated target cell association was studied by 
measuring the binding of the immuno-enzymosomes to
human ovarian cancer cells in vitro. The liposomes were 
incubated with the cells in suspension during 1 h at 
room temperature. After removal of the unbound li- 
posomes, the enzyme activity was determined. This 
method does not allow to measure the degree of cell 
d FabVragment 
-E enzyme 
Fig. 1. Schematic representation of the concept of antibody-directed enzyme prodrug therapy with immuno-enzymosomes. The immuno-enzymo- 
somes are first allowed to bind to the target cells. Then a prodrug is given, which is activated by the immuno-enzymosomes in close proximity of 
the target cell. The active drug can subsequently kill the cell. 
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binding of immunoliposomes as they do not contain 
enzymes. As shown in Fig. 2, the immuno-enzymo- 
somes showed a higher binding affinity for OVCAR-3 
cells than for A2780 cells which lack the antigen for 
OV-TL3 (P < 0.05). Enzymosomes howed only negligi- 
ble binding to both OVCAR-3 and A2780 cells. These 
results illustrate the importance of the presence of the 
specific antibody on the outside of the liposomes for 
obtaining specific cell binding and indicate that the tar- 
get binding capability of the Fab’-fragment is preserved 
upon coupling to the immuno-enzymosomes. This is not 
surprising as we estimate that around 400 Fab’ and only 
20 GUS molecules are present on the external surface 
of one immuno-enzymosome particle. Thus, even if the 
GUS molecules (MW 280 kDa) would hamper the tar- 
get recognition of the neighbouring, much smaller, 
Fab’-residues (MW 50 kDa), more than enough Fab’- 
fragments hould be available for binding to the target 
cells. 
The specific activation of the prodrug epi-glu at the 
target cells was investigated by first incubating 
OVCAR-3 cells with the various liposome types for 
1 h, washing the cells to remove unbound liposomes, 
and then exposing the cells to prodrug (final concentra- 
tion 10 PM). The presence of cell-associated liposomes 
did not inhibit the formation of a cell monolayer. As 
shown in Fig. 3, only pre-incubation of the target cells 
with immuno-enzymosomes resulted in an enhancement 
of the cytotoxicity of the added prodrug (epi-glu). Pre- 
treatment with enzymosomes or immunoliposomes was 
clearly ineffective. This demonstrates the ability of the 
cell-bound immuno-enzymosomes to convert the pro- 
drug to an agent with increased antineoplastic activity. 
These findings point to a potential usefulness of im- 
muno-enzymosomes in prodrug activation therapy. 
Several enzymes conjugated to monoclonal antibod- 
ies are currently being evaluated for selective activation 
of prodrugs at the tumor site. A theoretical advantage 
10, 
enzymosomes immuno-enzymosomes 
Fig. 2. In vitro cell binding of enzymosomes and immuno-enzymo- 
somes. NIH:OVCAR-3 cells (target cells; grey bars) or A2780 cells 
(control cells; white bars) were incubated with enzymosomes and im- 
muno-enzymosomes for 60 min at room temperature. After washing 
the cells with PBS containing 1% BSA to remove unbound liposomes, 
the enzymatic activity was determined. The cell binding is expressed 
as the absolute amount of (immuno)enzymosomes bound/106 cells. 
of the present immuno-enzymosome approach, as com- 
pared to the use of antibody-enzyme conjugates, is that 
much more than one enzyme molecule can be delivered 
to the tumor site by a single targeted liposome. This 
offers the possibility to increase the enzyme density at 
the target cell surface, and thereby to induce a higher 
efficiency of specific prodrug activation. To test this 
hypothesis, OV-TL3-enzyme conjugates were prepared 
as described previously [15]. The degree of cell binding 
and prodrug activation of the antibody-enzyme conju- 
gates appeared to be similar to that of the immuno- 
enzymosomes (results not shown). It should be realized, 
however, that the prodrug activation potential of im- 
muno-enzymosomes still can be considerably improved 
by increasing the amount of coupled enzyme per li- 
posome. However, one major recognized limitation of 
the immuno-enzymosome formulation used in the pres- 
Table I 
Characterization of liposome preparations 
Characteristics 
Coupling ratio Fab’ @g Fab’@mol TL) 
Coupling ratio GUS (ug GUS/pmol TL) 
Estimated number of Fab’ molecules per liposomeb 
Estimated number of GUS molecules per liposome 
Mean particle diameter @m) 
Polydispersity index 
MPB-PE Enzymosomes Immuno- Immuno- 
liposomes lipozomes enzymosomes 
_ _ 13.0 f 2.5 13.5 + 4.1 
_ 4.7 f 1.4 _ 4.0 + 1.6 
322 f 82 439 f 127 
26 f 8 _ 23f 10 
0.22 f 0.01 0.29 + 0.02 0.25 + 0.01 0.30 f 0.01 
0.14 f 0.01 0.25 r 0.05 0.17 f 0.03 0.25 + 0.03 
Mean values + standard deviation; the number of dispersions was at least 4 and in most cases 5. Liposomes were prepared and characterized 
according to the method described in section 2. 
“The coupling ratio &g Fab’/pmol TL and fig GUS/pmol TL) was determined using a protein determination assay, an enzyme-activity assay and 
a phosphate determination method as described in section 2.7. 
bathe number of Fab’ and GUS molecules coupled per liposome was estimated using the following assumptions: molecular weights of Fab’ 50 kDa 
and of GUS 280 kDa; an average number of 1.5 bilayers as determined for almost identically prepared PCIPSICHOL (10:1:4) liposomes [30]; a 
surface area of 1 x 10” pm2&mol TL. 
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1 2 3 4 
Fig. 3. In vitro antitumor activity of the prodrug epi-glu to OVCAR-3 
cells pretreated with liposomes. NIH:OVCAR-3 cells were pre-incu- 
bated with (1) PBS, (2) immunoliposomes, (3) enzymosomes and (4) 
immuno-enzymosomes for 60 min at 4°C. Cells were exposed to epi- 
glu (10 PM) for 24 h. Growth was measured with sulforhodamine-B 
after another 72 h. Relative cell growth is defined as cell growth 
relative to that of untreated cells (~100%). The mean cell growth of 
three separate experiments is shown. 
ent study is their tendency to aggregate above a cou- 
pling ratio of about 10 ,ug GUSlpmol TL. Currently, we 
attempt to optimize the immuno-enzymosome-medi- 
ated antitumor activity through enhancing enzyme sur- 
face density while avoiding the problem of liposome 
aggregation. Another point to be taken into account is 
that in this study over 400 Fab’ fragments and only 
about 20 GUS molecules were coupled to the liposomes. 
Less Fab’ fragments may already be sufficient for effi- 
cient cell binding. Therefore, attempts are presently 
being made to increase the amount of enzyme and de- 
crease the amount of Fab’ coupled on the surface of the 
immuno-enzymosomes. 
The enzyme /?-glucuronidase occurs in both prokar- 
yotic and eukaryotic organisms. In mammalian tissue 
the enzyme is present in lysosomes and microsomes and 
blood levels are low [24,25]. To investigate the immuno- 
enzymosome concept we used in this study GUS from 
E. coli. However, to prevent potential problems with the 
immunogenicity of bacterial GUS, in patients the 
human GUS enzyme should be used. It is generally 
accepted that the liposomal carrier in itself is not caus- 
ing serious immunogenic adverse reactions [26,27]. 
However, the association of a protein to the outside of 
the liposomes may induce an immune response. When 
immunoliposomes are administered only once, the im- 
mune response is not likely to affect the targeting effi- 
ciency because the targeting process will generally be 
faster than the establishment of an immune response 
[28]. However, in many therapeutic applications a mul- 
tiple injection schedule is needed. Immunogenic adverse 
reactions might by diminished by the administration of 
immunosuppressors [29]. In addition, the use of human 
or humanized monoclonal antibodies might reduce the 
risk for an immunogenic response. Also, it cannot be 
excluded that the combination of the enzyme and the 
monoclonal antibody on a liposome results in an even 
more increased immunogenicity. 
In summary, we have introduced and tested a new 
type of immunoliposomes which can effectively mediate 
the targeting of enzymes to be used for specific prodrug 
activation. Further studies will include the validation of 
the concept in tumor-bearing animals and will mainly 
focus on comparing the merit of immuno-enzymosomes 
with that of antibody-enzyme conjugates as well as of 
drug-containing immunoliposomes. 
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